Genovis launches GlycINATOR™ for analysis of ant

Genovis is launching GlycINATOR at the Well Characterized Biologicals conference in Washington DC on October 21. The product is the result of a collaboration between Genovis and a research group led by Mattias Collin at Lund University. GlycINATOR is a recombinant EndoS2* enzyme and the product is marketed as a single-use reagent to be used in characterization of monoclonal antibodies. Customers are mainly active in pharmaceutical and biotech companies. "It has been exciting to watch this development project progress to finished product. The project involves working closely with Lund University and Genovis’ relationship with innovative scientists is an important competitive advantage for strategic product development. GlycINATOR is an excellent addition to our product portfolio and strengthens our offering of glycan analysis products. In Washington we will also demonstrate a method in which IgGZERO can be used in combination with GlycINATOR to carry out a relatively simple quantitative analysis of high-mannose molecules on monoclonal antibodies. Mannose is a particularly important parameter to understand and handle when developing production processes for antibody-based drugs,” says Sarah Fredriksson, CEO of Genovis. Genovis has developed the product GlycINATOR, which can rapidly cleave carbohydrate molecules from IgG molecules. GlycINATOR is a recombinant enzyme. The yield is high, the reaction rate is fast and the enzyme does not affect the antibody molecule in general, but is very specific. Customers will primarily use the product for screening new drug substances, developing production processes and for quality control of new antibody-based drugs. *EndoS2 is a specific endoglycosidase from the microorganism Streptococcus pyogenes. EndoS2 is a patented enzyme and Genovis owns all rights. GlycINATOR™ is the brand name of the recombinant EndoS2. For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 (0)46 -101235 sarah.fredriksson@genovis.com ABOUT GENOVIS Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: 46 (0)31-745 50 00